PEN Stock Chart & Stats
$5560.11
$0.00(0.00%)
At close: 4:00 PM EDT
$5560.11
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4,191.95 - $5,560.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$219.47B
Enterprise Value$12.05K
Total Cash (Recent Filing)$205.27M
Total Debt (Recent Filing)$212.71M
Price to Earnings (P/E)78.5
Beta0.05
Next Earnings
Nov 04, 2026EPS Estimate
21.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.09
Shares Outstanding39,389,423
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.48
Price to Sales (P/S)8.62
P/FCF Ratio69.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6,218.66Price Target Upside11.84% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)84.93
Revenue Forecast (FY)$27.58B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRecent operating and free cash flow strength provides durable financial flexibility to fund R&D, commercial expansion, and working capital. Sustained positive cash conversion versus prior years supports reinvestment and reduces reliance on external financing across the 2–6 month horizon.
Improving Margins & Revenue GrowthMaterial top-line growth paired with mid-to-high 60% gross margins and recovering operating/net margins indicate the company can scale profitably. This margin profile, if sustained, supports long-term reinvestment and resilience to incremental cost pressures.
Recurring Disposable Model / Installed BaseA business model centered on single‑use disposables plus installed capital creates recurring, predictable per‑procedure revenue and clinical stickiness. An installed base encourages repeat purchases and supports durable revenue growth as procedure volume expands.
Bears Say
Earnings Volatility HistoryPast loss-making periods and sharp profitability swings highlight operational and demand sensitivity. Even with a recent rebound, volatility complicates multi‑period planning, capital allocation and investor confidence, and could re-emerge under adverse conditions.
Dependence On Procedure Volumes & ReimbursementRevenue is closely tied to hospital procedure volumes and reimbursement policies; changes in payer rules, coding, or hospital budgets can materially affect disposable demand. This structural exposure makes mid‑term revenue visibility sensitive to health‑system dynamics.
Pending Merger And Closing UncertaintyThe planned Boston Scientific acquisition creates near‑term strategic uncertainty until closing. Regulatory/closing risks and potential post‑deal reprioritization pose integration and product‑portfolio risks that could alter commercialization plans and investment cadence.
Penumbra News
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $4191.95 and its highest was $5560.11 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is $219.47B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Nov 04, 2026 which is in 94 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Jul 30, 2026. The company reported $15.266 earnings per share for the quarter, missing the consensus estimate of $20.158 by -$4.892.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 21.42.
How many shares outstanding does Penumbra have?
Penumbra has 39,389,423 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $15.266 in its last earnings report, missing expectations of $20.158. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in MX:PEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Penumbra Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6,218.66 (11.84% Upside)
$6,218.66 (11.84% Upside)
Blogger Sentiment
Bullish
MX:PEN Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.91%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
PEN Stock 12 Month Forecast
Average Price Target
$6,218.66
▲(11.84% Upside)











